Ravulizumab
ATC L04AJ02 · 10 markets · 24 records
AU 5 records · 4 strengths
- 1,100 mg/11 mLinjectionUltomiris
- 300 mg/3 mLinjectionUltomiris
- 100 mg/mLinjectionULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
US 3 records · 3 strengths
GB 3 records · 3 strengths
- 1,100 mg/11 mLinjectionUltomiris 300mg/30ml concentrate for solution for infusion vials
- 300 mg/3 mLinjectionUltomiris 300mg/30ml concentrate for solution for infusion vials
- 300 mg/30 mLinjectionUltomiris 300mg/30ml concentrate for solution for infusion vials
CA 2 records · 1 strengths
- 100 mg/1 mLliquidUltomiris
ES 2 records · 2 strengths
TW 2 records · 1 strengths
- 100 mginjectionUltomiris concentrate for solution for infusion 100mg/ml優力適輸注液100毫克/毫升、妥立瑞輸注液100毫克/毫升
HK 2 records · 1 strengths
2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 2 records · 2 strengths
- 1,100 mg/11 mLinjectionULTOMIRIS 1100 mg/11 mL, solution à diluer pour perfusion
- 300 mg/3 mLinjectionULTOMIRIS 1100 mg/11 mL, solution à diluer pour perfusion
SG 1 records · 1 strengths
- 100 mg/mLinjectionUltomiris concentrate for solution for infusion 100mg/ml
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
| Strength / form / release | US | GB | CA | AU | SG | ES | TW | HK | EU | FR |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,100 mg/11 mLRecorded as: 1.1 g/11 mL injection | Ultomiris 300mg/30ml concentrate for solution for infusion vials | Ultomiris | Ultomiris | ULTOMIRIS 1100 mg/11 mL, solution à diluer pour perfusion | ||||||
| 300 mg/3 mL injection | Ultomiris 300mg/30ml concentrate for solution for infusion vials | Ultomiris | Ultomiris | ULTOMIRIS 1100 mg/11 mL, solution à diluer pour perfusion | ||||||
| 100 mg injection | Ultomiris concentrate for solution for infusion 100mg/ml 優力適輸注液100毫克/毫升 妥立瑞輸注液100毫克/毫升 | |||||||||
| 100 mg/mL injection | ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial | Ultomiris concentrate for solution for infusion 100mg/ml | ||||||||
| 1,100 mg/11 mL liquid | Ultomiris | |||||||||
| 300 mg/3 mL liquid | Ultomiris | |||||||||
| 300 mg/30 mL liquid | Ultomiris | |||||||||
| 100 mg/1 mL liquid | Ultomiris | |||||||||
| 300 mg/30 mL injection | Ultomiris 300mg/30ml concentrate for solution for infusion vials | |||||||||
unknown | Ultomiris 100mg/ml | ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1100MG/11ML | Ultomiris |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
2 more strength/form rows are recorded only in CA · TW and are not shown in this table. Hay 2 filas de concentración/forma registradas solo en CA · TW que no se muestran en esta tabla. 另有 2 个规格/剂型仅在 CA · TW 有记录(未在本表显示)。 另有 2 個規格/劑型僅在 CA · TW 有記錄(未在本表顯示)。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.